Pregnancy: There are no adequate and well-controlled studies with ZIFAM SOVIR PLUS in pregnant women. Because animal reproduction studies are not always predictive of human response, ZIFAM SOVIR PLUS should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
If ZIFAM SOVIR PLUS is used in combination with ribavirin or peginterferon alfa/ribavirin, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for a period of time after the treatment has concluded. As a precautionary measure, it is preferable to avoid the use of ZIFAM SOVIR PLUS during pregnancy.
Lactation: The development and health benefits of breastfeeding should be considered along with the mother's clinical need for ZIFAM SOVIR PLUS and any potential adverse effects on the breastfed child from ZIFAM SOVIR PLUS or from the underlying maternal condition.